ARV-766
Metastatic Castration-Resistant Prostate Cancer
Phase 2Active
Key Facts
About Arvinas
Arvinas is a leader in the field of targeted protein degradation, developing novel therapeutics through its proprietary PROTAC® platform. The company has achieved significant clinical validation, with its lead oncology asset, vepdegestrant, demonstrating efficacy in pivotal trials for breast cancer, and its neuroscience candidate, ARV-102, showing compelling early-stage proof-of-concept in Parkinson's disease. Arvinas's strategy combines internal R&D with strategic partnerships, such as its major collaboration with Pfizer, to advance a deep pipeline and solidify its position as a platform innovator and drug developer.
View full company profileOther Metastatic Castration-Resistant Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| P-PSMA-ALLO1 | Poseida Therapeutics | Phase 1 |
| KEYTRUDA (pembrolizumab) | Merck | Phase 3 |
| MK-5684 | Merck | Phase 3 |
| TAK-280 | Thermo Fisher Scientific | Phase 2 |
| PNT2001 | Lantheus Holdings | Phase 3 |
| Bavdegalutamide (ARV-110) | Arvinas | Phase 2 |